Abstract:Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that is responsible for Chikungunya fever, which is characterized by fever, rash, and debilitating polyarthralgia. Since its re-emergence in 2004, CHIKV has continued to spread to new regions and become a severe health threat to global public. Development of safe and single dose vaccines that provide durable protection is desirable to control the spread of virus. The recombinant adeno-associated virus (rAAV) vectors represent promising vaccine platform to provide prolonged protection with a single-dose immunization. In this study, we developed a rAAV capsid serotype 1 vector based CHIKV vaccine and evaluated its protection effect against CHIKV challenge. The recombinant AAV1 encoding the full-length structural proteins of CHIKV (named as rAAV1-CHIKV-SP) was generated in vitro by transfecting the plasmids of AAV helper-free system into HEK-293T cells. The safety and immunogenicity of rAAV1-CHIKV-SP were tested in 4-week-old C57BL/6 mice. The antibody responses of the mice receiving prime-boost or single-dose immunization of the vaccine were determined by ELISA and plaque reduction neutralizing test. The immunized mice were challenged with CHIKV to evaluate the protection effect of the vaccine. The rAAV1-CHIKV-SP showed remarkable safety and immunogenicity in C57BL/6 mice. A single dose intramuscular injection of rAAV1-CHIKV-SP elicited high level and long-lasting antibody responses, and conferred complete protection against a heterologous CHIKV strain challenge. These results suggest rAAV1-CHIKV-SP represents a promising vaccine candidate against different CHIKV clades with a simplified immunization strategy. Recently, a live attenuated CHIKV was approved as the first vaccine to combat the virus infection. Despite the general safety of this vaccine, several severe chikungunya-like adverse reactions have been reported, and the long-term safety should be assessed after marketing, highlighting the urgent need to develop more safe and effective vaccines against CHIVK. The rAAV vectored vaccines against several viruses such as SARS-CoV-2, HIV, HCV and Nipah virus have been developed. Here, we constructed a rAAV capsid serotype 1 based CHIKV vaccine that encoded the full-length structural proteins of CHIKV (rAAV1-CHIKV-SP), and evaluated the safety, immunogenicity and protection effect of the vaccine. The results demonstrated that a single dose immunization of the vaccine induced high level and long-lasting CHIKV-specific antibodies and neutralizing antibodies, and completely protected against CHIKV challenge in C57BL/6 mice. Our study suggested that the rAAV1-CHIKV-SP represents a promising vaccine candidate to prevent CHIKV infection.

Construction and immunogenicity of an mRNA vaccine against chikungunya virus

mRNA Vaccine Designing Using Chikungunya Virus E Glycoprotein through Immunoinformatics-Guided Approaches

An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses

A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice

Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions

Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells

A chikungunya fever vaccine utilizing an insect-specific virus platform

From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine

Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis

A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice

Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines

Chikungunya vaccines: advances in the development and prospects for marketing approval

Immunogenicity Analysis of Chikungunya Virus DNA Vaccine Based on Mutated Putative N-Linked Glycosylation Sites of the Envelope Protein

Live-attenuated RNA hybrid vaccine technology provides single-dose protection against Chikungunya virus

Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate

A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

High titer self-propagating capsidless Chikungunya virus generated in Vero cells as a strategy for alphavirus vaccine development

The Chimeric Chaoyang-Zika Vaccine Candidate Is Safe and Protective in Mice

A Small Antigenic Determinant of the Chikungunya Virus E2 Protein Is Sufficient to Induce Neutralizing Antibodies which Are Partially Protective in Mice

Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure

The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection